Researchers from Biotech Research & Innovation Centre (BRIC) at University of Copenhagen have now identified a
gene-family that is essential for regulating the differentiation potential of stem cells and normal development. This provides new perspectives for the development of cancer drugs.
How stem cells work
All living organisms, including human beings, consist of a number of specialised cell types that all originate from the same type of primal cell; the embryonic stem cell. Stem cells can develop into any type of cell through a carefully regulated process referred to as cellular differentiation. During differentiation, specific genes are switched on while other genes are switched off. The genes that are activated during differentiation determine which type of cell the stem cell will become. The result is that cells in a particular organ, e.g. a liver, only express genes specific to that organ.
What the research showed
Director of BRIC, Professor Kristian Helin led the research team consisting of Jesper Christensen, Karl Agger and Paul Cloos. Last year, the same research group published an article in Nature on how a group of Jumonji proteins regulate the growth of cancer cells and are involved in the development of specific cancer types.
BRIC’s new results show that a different subgroup of Jumonji proteins is essential for cellular differentiation. The Jumonji enzymes can turn off, or inactivate, particular genes that play an important part in embryogenesis. The conclusions are based on studies of the nematode (roundworm) C. elegans and studies of mouse embryonic stem cells. The C. elegans studies were carried out in collaboration with another of BRIC’s research groups, led by Associate Professor Lisa Salcini.
The results are published in the current issue of Cell.
Source: University of Copenhagen homepage.